Lck is a Src-family tyrosine kinase that is expressed predominantly in T cells, where it plays important roles in T-cell activation. Lymphostin was isolated from Streptomyces sp. as an inhibitor of Lck. As previously reported, lymphostin inhibited Lck (IC 50 0.05 mM) and the mixed lymphocyte reaction (IC 50 0.009 mM). We have now examined the mechanism of inhibition by lymphostin. Lymphostin inhibited protein-tyrosine kinase activity in Jurkat T cells, demonstrating the eŠec-tiveness of the compound at the cellular level. Furthermore, lymphostin suppressed delayed-type hypersensitivity in mice. However, the inhibitory activity against Lck at the cellular level was weaker than that against the mixed lymphocyte reaction. Thus, we examined the eŠects of lymphostin on other kinases. Interestingly, lymphostin also inhibited phosphatidylinositol 3-kinase (IC 50 0.001 mM). Consequently, we conclude that lymphostin inhibits the mixed lymphocyte reaction and delayed-type hypersensitivity not only through the blockade of Lck, but through the blockade of phosphatidylinositol 3-kinase as well.
Key words: Lck; phosphatidylinositol 3-kinase; immunosuppressant; T lymphocyte; protein tyrosine kinase Lymphocyte kinase, Lck (p56 lck ), is a Src-family tyrosine kinase that is expressed exclusively in lymphoid cells, predominantly in thymocytes and peripheral T cells, where it plays important roles in T-cell development and activation. 1) Lck binds to the cytoplasmic domains of CD4 and CD8 T-cell co-receptors, 2) and following T-cell receptor stimulation, phosphorylates T-cell receptor zeta chains, which then recruit ZAP-70 kinase to promote T-cell activation.
3) A mutant human Jurkat T cell line lacking functional Lck fails to respond to anti-T cell receptor antibodies, 4) and Lck knock-out mice are defective in thymocyte development and do not have T cell-mediated eŠects including allo-skin graft rejection.
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Cyclosporin A (CsA) and FK506 have been used as clinically eŠective immunosuppressants. CsA and FK506 form complexes with immunophilins such as cyclophilin and FK506 binding protein (FKBP), respectively. The drug-immunophilin complexes suppress various T cell-related immune responses, such as the production of interleukin 2 (IL-2), through the inhibition of the Ca 2+ -and calmodulin-dependent phosphatase, calcineurin. 8) This mechanism of action, however, leads to severe side eŠects, i.e. nephrotoxicity, neurotoxicity, and diabetogenicity, which limit their clinical use. Accordingly it is considered that Lck inhibitors could be novel potential immunosuppressants with diŠerent mechanisms of action from these drugs.
Recently, we reported that in the course of screening for Lck inhibitors from microorganisms, we found a novel microbial alkaloid, lymphostin ( Fig. 1) , possessing a pyrrolo [4,3,2-de] quinoline skeleton, which is rare among natural products. 9, 10) The IC50 for enzyme inhibition was 0.05 mM. In previous studies, the immunosuppressive activity of lymphostin was assessed using the mixed lymphocyte reaction (MLR), which is a measure of T-cell activation followed by IL-2 dependent T-cell proliferation. This is considered to be an in vitro model of allograft rejection. Lymphostin was a potent inhibitor of the MLR, with an IC50 of 0.009 mM, while the IC50 of CsA was 0.05 mM. The IC50 for the antiproliferative activity of lymphostin against NFS-60, a murine myeloid leukemia cell line, was 0.16 mM.
In this study, we examined the mechanism of inhibition of Lck by lymphostin. Lymphostin inhibited autophosphorylation of Lck, as well as Lck-mediated phosphorylation of exogenous substrate, and was eŠective at the cellular level. However, the inhibitory activity against the protein-tyrosine kinase activity of Lck at the cellular level occurred at drug concentrations that were much higher than those required for inhibition of MLR. These results suggest that lymphostin may inhibit MLR through a mechanism(s) other than the blockade of Lck. We, therefore, examined the eŠects of lymphostin on other protein kinases and phosphatidylinositol 3-kinase (PI3-kinase). Interestingly, lymphostin also potently inhibited the kinase activity of PI3-kinase, with an IC50 of 0.001 mM. PI3-kinase is coupled to multiple T-cell molecules (reviewed by Ward et al. 11) ). The PI3-kinase inhibition by lymphostin may be involved in the MLR inhibition. Thus, we also examined the mechanism of inhibition of PI3-kinase activity by lymphostin.
In addition, we report the immunosuppressive activity of lymphostin in a mouse experimental model. Our data indicate that lymphostin is a potent immunosuppressant with inhibitory activities against Lck and PI3-kinase.
Materials and Methods
Reagents and materials. Lymphostin was isolated from the fermentation broth of Streptomyces sp. KY11783 in our laboratories, as described previously. 9) The peptide substrate (Tyr-Ala-Glu)7 used in the assay of Lck activity was synthesized in our laboratories. Lck was partially puriˆed from bovine thymus according to the method of Cushman et al.
12) PI3-kinase was partially puriˆed from bovine thymus essentially as described by Shibasaki et al. 13) [g-32 P]ATP and anti-phosphotyrosine antibody PY20 conjugated to horseradish peroxidase were purchased from Amersham Corp. (Tokyo, Japan); anti-Lck (Nterminal) antiserum and anti-PI3 kinase p85 antiserum complexed to protein G-Sepharose beads were from Upstate Biotechnology, Inc. (Lake Placid, NY); OKT3 was from Becton Dickinson (Franklin Lakes, NJ). All other reagents were of analytical grade.
Enzyme assay. The activity of Lck was assayed using a peptide substrate (Tyr-Ala-Glu)7 14) and [g-32 P] ATP in the presence of various concentrations of the test compounds, as described previously.
9) The peptide (0.5 mg W ml) was phosphorylated in a reaction mixture comprising 12 mM MOPS (pH 7.5), 12 mM MgCl2, 60 mM Na3VO4, partially puriˆed Lck (156 mg W ml), 50 mM [g-32 P] ATP (1000-2000 cpm W pmol), and 1z DMSO as a carrier for the compounds in aˆnal volume of 25 ml. After a 60-minute incubation at 309 C without ATP, the reaction was started by the addition of [g-32 P] ATP at 309 C and stopped by the addition of 25 ml of 10z trichloroacetic acid, after 15 minutes. The acid-precipitable materials were collected on a nitrocellulose membraneˆlter and washed with 10z trichloroacetic acid. The radioactivity on theˆlter was measured in toluene scintillation ‰uid using a scintillation counter.
The activity of autophosphorylation of Lck was measured using an immunocomplex assay. Jurkat T cells were lysed in lysis buŠer containing 1z Nonidet P-40, 50 mM Tris-HCl, pH 8.0, and 2 mM EDTA by rotating for 30 min, and the lysate was centrifuged at 12000 rpm for 20 min at 49 C. The supernatants were incubated with rabbit anti-mouse IgG (DAKO; Kyoto, Japan), followed by Protein G-Sepharose beads prepared as a 50z (w W v) suspension. The cleared lysates were incubated with the anti-Lck (N-terminal) antiserum, followed by protein GSepharose beads prepared as a 50z (w W v) suspension. After washing, the beads were suspended in 20 ml of a reaction buŠer containing 40 mM PIPES, pH 7.1, and 10 mM MnCl2. The mixture was incubated at 309 C for 10 min in the presence of various concentrations of the test compounds. [g-32 P] ATP (10 mCi W assay) was added to start the reaction, and the mixture was incubated at 309 C for 10 min. The reaction was stopped by the addition of 40 ml of 2× SDS sample buŠer. The samples were boiled for 5 min, and the supernatants were run on a 5-20z SDS polyacrylamide gel. The radioactivity on the dried gel was measured with a Fuji BAS2000 Bioimaging Analyzer (Fujiˆlm; Tokyo, Japan).
The activity of PI3-kinase was measured as described previously. 15) In an ordinary solution assay, partially puriˆed PI3-kinase from calf thymus tissue was used at aˆnal concentration of 20 ng W ml. In the case of the immunocomplex assay, PI3-kinase activity was measured in immunoprecipitates with anti-PI3-kinase p85 antiserum complexed with protein G-Sepharose beads. Jurkat T cells were harvested, washed in serum-free RPMI 1640 medium and lysed in 1z Nonidet P-40, 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM sodium orthovanadate, 5 mM EDTA, and 1 mM phenylmethylsulfonyl ‰uoride for 20 min. The lysates were clariˆed by centrifugation at 12000 rpm for 20 min. The clariˆed lysates were cleared by incubation with normal rabbit serum and protein G-Sepharose beads. The cleared lysates were incubated with the anti-PI3-kinase p85 antiserum at 4 mg W ml, followed by protein G-Sepharose beads prepared as a 50z (w W v) suspension. The beads were washed sequentially with Nonidet P-40 lysis buŠer, LiCl solution (0.5 M LiCl, 0.1 M Tris-HCl, pH 7.5), distilled water, and washing buŠer (0.1 M NaCl, 1 mM EDTA, 20 mM Tris-HCl, pH 7.5). The partially purifed enzyme or the immunoprecipitates were suspended in 50 ml of a buŠer containing 20 mM TrisHCl, pH 7.5, 20 mM MgCl2, 100 mM NaCl, and 0.5 mM EGTA. Then, 1 ml of 10 mg W ml PI dissolved in dimethyl sulfoxide was added to the reaction mixture to make micelles of PI. The mixture was incubated at 309 C for 10 min in the presence of various concentrations of the test compounds. [g-32 P] ATP (1.0 mCi W assay;ˆnal concentration, 10 mM) was added to start the reaction, and the mixture was incubated at 309 C for 60 min. The reaction was stopped by the addition of 100 ml of chloroform, methanol and 11.6 N HCl (100:200:2). Following centrifugation, the lower organic phase was collected for thinlayer chromatography on silica gel plates to be developed in chloroform, methanol, 25z ammonium hydroxide and water (43:38:5:7). The radioactivity on the dried plate was made visible after development with a Fuji BAS2000 Bioimaging Analyzer.
Cells and cell culture. The human Jurkat T cells were kept in RPMI 1640 medium with 10z fetal calf serum at 379 C in a humidiˆed, 5z CO2 atmosphere.
Intracellular phosphotyrosine measurements. Inhibition of OKT3-stimulated tyrosine phosphorylation in Jurkat T cells was measured as follows. Cells (4× 10 6 in 2 ml of medium) were incubated for 30 min with test compounds before a 6-min incubation with 10 mg W ml of OKT3. Reactions were stopped by the addition of cold phosphate-buŠered saline. Cells were harvested, washed in cold PBS, and lysed in 1z Triton X-100, 20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 10z glycerol, 1 mM sodium orthovanadate, 2 mM EDTA, 1 mM ( p-amidinophenyl)methanesulfonyl ‰uoride, 20 mM leupeptin, and 0.15 U W ml aprotinin for 20 min. Insoluble materials were removed by centrifugation at 14000 rpm for 10 min. The lysates were added to 2×sample buŠer and boiled at 1009 C for 5 min. For immunoblots, the samples were separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The blots were blocked with 1z bovine serum albumin in 10 mM Tris-HCl, pH 7.5, 100 mM NaCl and 0.1z Tween-20. Blots were incubated with anti-phosphotyrosine antibody, PY20, conjugated with horseradish peroxidase followed by washing and then detected with ECL system (Amersham Corp.; Tokyo, Japan). The densities of p20 band were measured using a Pdi scanner (Howtek Inc.; Hudson, NH).
Delayed-type hypersensitivity (DTH) reaction. To induce DTH 16) to trinitrophenyl (TNP), 0.1 ml of 10 mM trinitrobenzene sulfonic acid (TNBS) solution (pH 7.4) was subcutaneously (s.c.) injected into two separate sites on the dorsal ‰anks of the Balb W c mice. The compound dissolved in 10z DMSO was intraperitonealy injected (i.p.) once a day from day 0 to day 4. Ten percent DMSO was used as the solvent control. Challenge was done 5 days later by injecting 0.05 ml of 10 mM TNBS solution (pH 7.4) into the right footpad. Twenty-four hours after the footpad challenge, DTH reactivity was assessed by measuring the swelling of the footpad. The magnitude of the DTH was expressed as the increment of the thickness of the challenged right footpad, compared with the untreated left footpad. Each group consisted ofˆve mice. Lymphostin was dissolved in DMSO and administered by i.p. injection for 5 consecutive days, beginning on the day of sensitization.
Results

Mechanism of inhibition of Lck by lymphostin
We have already reported that lymphostin inhibits phosphorylation of peptide substrate (Tyr-Ala-Glu)7 by Lck from bovine thymus, in a concentrationdependent manner. To identify the mechanism of the inhibition of Lck by lymphostin, we examined the time dependency of the inhibitory action. Lymphostin was incubated with the reaction mixture for diŠerent times before the addition of ATP. The reaction was started by the addition of ATP and incubated for 15 min. Incubation in the absence of the drug for up to 60 min had little eŠect on the enzyme activity of Lck (data not shown). The inhibitory activity of lymphostin was dependent on theˆrst incubation times (Fig. 2) . The IC 50 in theˆrst incubation times of 0, 5, 10, 30, and 60 min were 0.6, 0.4, 0.2, 0.1, and 0.05 mM, respectively. The results suggested that lymphostin inhibits Lck in a slow-binding manner.
T-cell receptor stimulation induces Lck autophosphorylation, which increases the enzyme activity of Lck. Thus, we examined the inhibitory activity of lymphostin against Lck autophosphorylation in vitro. Lck immunocomplexes from human Jurkat T cells were incubated with lymphostin for 10 min, and the reaction was started by the addition of ATP. Lymphostin inhibited Lck autophosphorylation in a dose-dependent manner. A representative autoradiogram is shown in Fig. 3 . The IC50 of autophosphorylation was 0.33 mM, which was similar to the IC50 for the phosphorylation of peptide substrate in a 10-min incubation (0.2 mM). 
EŠects of lymphostin on T-cell tyrosine phosphorylation
Signaling through the T-cell receptor has been shown to cause rapid increases in tyrosine phosphorylation of T-cell receptor zeta chain and other substrates. 17) A mutant of the human Jurkat T-cell line lacking Lck kinase functiuon was defective in the induction of tyrosine phosphorylation, indicating that Lck kinase activity is essential for tyrosine phosphorylation through the T-cell receptor. 4) Tyrosine kinase inhibitors such as genistein, herbimycin, and PP1 were reported to inhibit T-cell-receptor-induced T-cell activation. [18] [19] [20] We examined the eŠects of lymphostin on anti-CD3-stimulated tyrosine phosphorylation in human Jurkat T-cells. Human Jurkat Tcells were treated with 10 mg W ml of antibody OKT3 alone and with OKT3 after a 30-min incubation with lymphostin or staurosporine. After lysis in 1z Triton X-100, T-cell tyrosine phosphorylation was detected using Western blotting with anti-phosphotyrosine antibody. A representative phosphotyrosine blot is shown in Fig. 4 . OKT3 induced tyrosine phosphorylation of an approximately 23-kDa protein.
Lymphostin inhibited tyrosine phosphorylation in a dose-dependent manner. The IC50 was 0.2 mM, as found by measuring the p23 bands. Lymphostin also reduced constitutive tyrosine phosphorylations. Lymphostin proved to be eŠective at the cellular level, at least in the decreased tyrosine phosphorylation of T-cell proteins. However, the concentrations required for inhibition of tyrosine phosphorylation were greater than those required to inhibit MLR. This result suggested that there may be additional targets of lymphostin.
Inhibition of PI3-kinase by lymphostin
In order to identify additional targets of lymphostin, we examined the eŠects of lymphostin on various kinases. We found that lymphostin inhibited PI3-kinase at an approximately 50-fold lower concentration than that required for Lck inhibition. PI3-kinase activity was measured using the [g-32 P] ATP radioisotopic method. Phosphorylated products of PI were extracted and separated by TLC. The eŠects of lymphostin on PI3-kinase activity are shown in 1 and lane 4) . After the immunoprecipitates were washed 5 times with washing buŠer used in their preparation, PI3-kinase activity in the washed immunoprecipitates was assayed. The lipid products were extracted and separated by TLC as described under``Materials and Methods''. An autoradiogram of the TLC is shown with the position of spots corresponding to PI-3P and origin (Ori) indicated by arrows. Data shown are from an experiment that is representative of two independent experiments with the same result. Next, we examined the reversibility of the inhibition of PI3-kinase by lymphostin. Jurkat T-cell PI3-kinase was immobilized on protein G-Sepharose beads. The enzyme-immunocomplex was then treated with lymphostin at 0.01 mM for various times. PI3-kinase activity was completely inhibited by 0.01 mM of lymphostin. To measure the reversibility of the inhibition, residual PI3-kinase activity in washed enzyme immunocomplexes was estimated. Inhibition after a 30-min incubation with 0.01 mM of lymphostin was not reversed by washing out the inhibitor (Fig. 6,  lane 1 and lane 4) . Further, the inhibitory activity by lymphostin was dependent on the incubation time (Fig. 6, lane 2, lane 3, and lane 4) . Taken together, these results suggest that lymphostin inhibits PI3-kinase activity by interacting irreversibly with the enzyme.
Suppressive eŠect on delayed-type hypersensitivity (DTH) in mice by lymphostin
We have previously shown that lymphostin inhibits the MLR in vitro with an IC50 of 0.009 mM. We next assessed the immunosuppressive activity of lymphostin in vivo using the mouse DTH experimental model. As shown in Table 1 
Discussion
In this study, we show that a novel immunosuppressant, lymphostin, inhibited autophosphorylation of Lck as well as Lck phosphorylation of exogenous substrate, and anti-CD3-induced protein tyrosine phosphorylation in Jurkat T-cells. In a mouse experimental model, lymphostin inhibited DTH in vivo (1 mg W kg×5 i.p.: 65z). However, the inhibitory activity against Lck in the cellular level was less potent (IC50 0.2 mM) than that against MLR (IC50 0.009 mM). These results suggest that there may be another target for lymphostin besides Lck. Thus we examined the eŠects of this compound on various kinases. As a result, we found that lymphostin was a potent inhibitor of PI3-kinase. The IC50 was 0.001 mM, which was lower than that of wortmannin, a known potent PI3-kinase inhibitor (IC50 0.003 mM 15) ). PI3-kinase catalyzes the formation of D-3 phosphoinositide lipids by transferring the terminal phosphate of ATP to the D-3 position of the inositol head groups of phosphoinositide lipids (reviewed by Kapeller and Cantley 21) ; Rameh and Cantley 22) ). PI3-kinase is composed of a catalytic p110 subunit and a regulatory p85 subunit that binds tyrosylphosphorylated proteins via its src homology 2 domains. P85 also has a src homology 3 domain that can interact with proteins containing proline-rich regions. Considerable evidence indicates that PI3-kinase may function as a key component of multiple signaling pathways, including T-cell activation. The accumulation of D-3 phosphoinositide lipids occur in response to ligation of several surface molucules involved in T-cell activation and proliferation, including the T-cell receptor, 23) CD4, 24, 25) CD28, 26) CD2, 23) CTLA-4, 27) and interleukin 2 receptor. 28) Lymphostin inhibited the PI3-kinase activity of a partially puried preparation from calf thymus and of an anti-PI3-kinase p85 immunoprecipitated from human Jurkat T-cells, with an IC50 of 0.001 mM. This potency is consistent with the eŠects of the inhibitor on cellular response of MLR. Therefore, lymphostin is considered to inhibit the MLR and DTH not only through the blockade of Lck but also through the blockade of PI3-kinase.
Wortmannin, which is a potent and selective PI3-kinase inhibitor, has immunosuppressive activity in whole animals. 29) Wortmannin treatment of allogeneic donor lymphocytes in vitro failed to generate a signiˆcant graft-vs-host disease in irradiated mouse recipients. 30) Wortmannin inhibited the MLR with an IC50 of 0.027 mM (data not shown), but it did not inhibit the Lck (IC50À100 mM, data not shown). Together with this study, these data also suggest that PI3-kinase and Lck could be potential targets of immunosuppressants.
To investigate the involvement of Lck and PI3-kinase independently, derivatives of lymphostin with speciˆc inhibitory activity need to be synthesized. Figure 4 indicated that lymphostin inhibited the phosphorylation of constitutively tyrosine-phosphorylated proteins as well as p23. So we cannot rule out possible involvements of other tyrosine kinase inhibitions.
The results obtained from the incubation studies indicated that lymphostin inhibited Lck and PI3-kinase through a direct interaction with the enzymes and that the inhibition was irreversible. Lymphostin has a b-methoxy enone group that would be attacked by an amino group of the protein to form a vinylogous amide. Irreversible inhibition of Lck and PI3-kinase by lymphostin could be explained by such a covalent reaction of the compound with the enzyme proteins.
The biological roles of PI3-kinase have been examined by using PI3-kinase inhibitors such as wortmannin as molecular probes. However, the function of PI3-kinase has not yet been fully identiˆed. Therefore, lymphostin and wortmannin will be good tools to study the role of this enzyme.
Many kinase inhibitors have been developed, since kinases are considered potential targets for the treatment of a variety of diseases, such as cancer, atherosclerosis, and psoriasis, and a large number of in‰am-matory responses, such as septic shock. 31) Potent kinase inhibitors, such as staurosporine and wortmannin, have been found in microorganisms. It is noteworthy that lymphostin has potent kinase inhibitory activity, but its structure diŠers from those of known kinase inhibitors. Therefore, lymphostin provides a promising lead for developing novel kinase inhibitors.
